Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD

Elife. 2021 Jul 27:10:e69320. doi: 10.7554/eLife.69320.

Abstract

Psychoactive drugs can transiently perturb brain physiology while preserving brain structure. The role of physiological state in shaping neural function can therefore be investigated through neuroimaging of pharmacologically induced effects. Previously, using pharmacological neuroimaging, we found that neural and experiential effects of lysergic acid diethylamide (LSD) are attributable to agonism of the serotonin-2A receptor (Preller et al., 2018). Here, we integrate brain-wide transcriptomics with biophysically based circuit modeling to simulate acute neuromodulatory effects of LSD on human cortical large-scale spatiotemporal dynamics. Our model captures the inter-areal topography of LSD-induced changes in cortical blood oxygen level-dependent (BOLD) functional connectivity. These findings suggest that serotonin-2A-mediated modulation of pyramidal-neuronal gain is a circuit mechanism through which LSD alters cortical functional topography. Individual-subject model fitting captures patterns of individual neural differences in pharmacological response related to altered states of consciousness. This work establishes a framework for linking molecular-level manipulations to systems-level functional alterations, with implications for precision medicine.

Trial registration: ClinicalTrials.gov NCT02451072.

Keywords: computational model; functional connectivity; gene expression; human; neuroscience; pharmacological neuroimaging.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain / diagnostic imaging
  • Brain / drug effects*
  • Brain / pathology
  • Brain / physiopathology
  • Consciousness / drug effects
  • Humans
  • Lysergic Acid Diethylamide / pharmacology*
  • Mental Disorders / diagnostic imaging
  • Mental Disorders / drug therapy*
  • Mental Disorders / pathology
  • Mental Disorders / physiopathology
  • Models, Theoretical*
  • Neuroimaging / methods
  • Receptors, Serotonin, 5-HT2 / drug effects
  • Transcriptome*

Substances

  • Receptors, Serotonin, 5-HT2
  • Lysergic Acid Diethylamide

Associated data

  • ClinicalTrials.gov/NCT02451072